Celltrion acquires Australian approval of trastuzumab biosimilar ‘Herzuma’

Published: 2018-08-07 08:31:00
Updated: 2018-08-07 08:48:55

Celltrion recently announced they acquired sales approval of therapeutic antibody biosimilar for breast cancer and stomach cancer ‘Herzuma(generic name: trastuzumab)’ from the Australian Therapeutic Goods Administration.

‘Herzuma,’ the only trastuzumab biosimilar which acquired the approval in A...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.